As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices, while a Democratic congressman from Vermont announced a bill to allow the importation of insulin from Canada and other countries.
As part of its investigation into drug pricing, the Senate Finance Committee is launching a bipartisan probe into insulin prices.
In addition, a Democratic congressman from Vermont, Peter Welch, unveiled a bill to allow the importation of insulin from Canada and other countries.
On Friday, Senate Finance Committee Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Oregon, sent 3 letters to the heads of insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi seeking information regarding recent price increases of up to 500% or more.
Sanofi’s chief executive officer, Olivier Brandicourt, is already scheduled to testify Tuesday before the committee as part of its probe into drug pricing, which started last month. According to 1 report, Brandicourt is looking to lay the blame for high prices at the feet of pharmacy benefit managers (PBMs) and the impact that rebates have on what patients wind up paying.
In the letters, Grassley and Wyden seek detailed information about 30 different points related to drug pricing, research and development costs, rebate agreements, PBM pacts, patient assistance programs, donations to patient advocacy groups, production and marketing and advertising, revenues and gross margins from selling insulin, and the companies’ funding of patient assistance programs. The companies have until March 8 to respond.
In a statement, the senators said that the price of Eli Lilly’s Humalog increased from $35 to $234 between 2001 and 2015, a 585% increase. The price of Novo Nordisk’s Novolog increased from $289 to $540 between 2013 and 2019, an approximately 87% increase. The price of Sanofi’s Lantus increased from $244 to $431 between 2013 and 2019, an approximately 77% increase.
The Senate Finance Committee oversees Medicare and Medicaid; the letter notes that in 2012, Medicare Part D spending for Lantus was $1.1 billion; by 2016, Part D spending was $1.7 billion. Medicaid spending swelled from $314 million to $785 million.
Last month, the finance committee held its first hearing on drug prices, and as part of that session it heard from a mother who talked about her son rationing his insulin because of the $1700 monthly cost.
Rationing is common among patients with diabetes, said an endocrinologist who appeared with Welch last week when he introduced his bill at a news conference. Welch’s bill would allow patients to import insulin from Canada and other countries. The FDA and HHS have not endorsed that option, given concerns with quality control, counterfeits, and other issues.
In January, Grassley and Senator Amy Klobuchar, D-Minnesota, also introduced a bill that would allow imports from Canada.
The rise in insulin prices was the main factor in the increase in healthcare spending over 4 years for poeple with type 1 diabetes, a report from the Health Care Cost Institute said last month.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.